Venue:
Palau de la Música
Rodrigo Meeting Room
Paseo de la Alameda, 30
46030 Valencia (Spain)

language
The official language of the Symposium is English. Simultaneous translation into Spanish will be provided.

Credits
Accredited by the European Society for Medical Oncology Educational Committee for its medical oncology certification approval program with 8 ESMO MORA category 1 points.

Under the auspices of
The Spanish Ovarian Cancer Research Group

Organized by:
Andrés Cervantes (ESMO, GEICO)
Antonio González (ESMO, GEICO)
Jan B. Vermorken (ESMO)
Andrés Poveda (ESMO, GEICO)

Valencia, Spain, 4th March 2011

Optimal Therapy. Update
Advanced Ovarian Cancer:
ONCOLOGY UPDATE 2011
08:30 Welcome
David Kerr
ESMO President
Manuel Llombart
General Manager, Fundación Instituto Valenciano de Oncología, Valencia, Spain

08:45-09:25 Keynote Lecture: Molecular Biology In Ovarian Cancer
Robert C. Bast Jr
The University of Texas, MD Anderson Cancer Center, Houston (Texas), USA

SESSION-1 EARLY DETECTION
CHAIRS: Elise C. Kohn
National Cancer Institute, Bethesda (Maryland), USA
Andrés Cervantes
Hospital Clínico Universitario, Valencia, Spain

09:25-09:45 Defining the Target for Early Detection
Patrick O. Brown
Stanford University School of Medicine, Stanford (California), USA

09:45-10:05 Designing Early Detection Programs for Ovarian Cancer
Nicole Urban
Fred Hutchinson Cancer Research Center, Seattle (Washington), USA

10:05-10:20 Discussion

SCIENTIFIC PROGRAM
SESSION-2 PRIMARY OVARIAN CANCER PART-1
CHAIRS: Jonathan Berek
Stanford University School of Medicine, Stanford (California), USA
Sergi Martínez
Hospital Clínic, Barcelona, Spain

10:20-10:40 Quality Control in Ovarian Cancer Surgery
Mark P. Fitzgibbons
Royal Hospital for Women, Randwick, Australia

10:40-11:00 Is the use of PICTCT Leading to Stage Migration?
Maria El. van der Burg
Erasmus Medical Center, University Medical Center Rotterdam, The Netherlands

11:00-11:20 Preoperative Serum CA125 Levels and Risk of Suboptimal Cytoreduction in Ovarian Cancer
Sang-Yoon Park
Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Ilsan-gu Madu-dong, Goyang, Republic of Korea

11:20-11:30 Discussion

SESSION-3 PRIMARY OVARIAN CANCER PART2
CHAIRS: Nicoletta Colombo
European Institute of Oncology, Milan, Italy
Jan B. Vermorken
Antwerp University Hospital, Edegem, Belgium

12:00-12:45 Dose Densified Therapy in First Line Treatment of Ovarian Cancer?
PRO: Noriyuki Katsumata
National Cancer Center Hospital, Tokyo, Japan
CON: Maria El. van der Burg
Erasmus Medical Center, University Medical Center Rotterdam, The Netherlands

12:45-13:00 Follow up with CA125 After Primary Therapy of Advanced Ovarian Cancer has Major Implications for Treatment Outcome and Trial Performances
PRO: Sandro Pignata
National Cancer Institute Fondazione Pascale, Naples, Italy
CON: Gordon Rustin
Mount Vernon Cancer Center, Northwood (Middlesex), United Kingdom

13:00-13:15 Discussion

13:15-14:55 Lunch

SESSION-4 NEW THERAPIES IN OVARIAN CANCER
CHAIRS: Stanley B. Kaye
The Royal Marsden Hospital, London, United Kingdom
Antonio González-Martín
Centro Oncológico MD Anderson International España, Madrid, Spain

17:30-18:10 Antiangiogenic Therapy
PRO: Robert A. Burger
Fox Chase Cancer Center, Philadelphia (Pennsylvania), USA
CON: Maurie Markman
Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia (Pennsylvania), USA

18:10-18:25 Parp Inhibition
Cristiana Sessa
Ospedale San Giovanni, Bellinzona, Switzerland

18:25-18:45 Other New Therapies
David R. Spriggs
Memorial Sloan-Kettering Cancer Center, New York (New York), USA

18:45-19:00 Discussion

19:00-19:15 Remarks and Conclusions
Andrés Poveda
Fundación Instituto Valenciano de Oncología, Valencia, Spain

10:30-10:50 Discussion

SESSION-5 RANDOMIZED TRIALS IN OVARIAN CANCER
CHAIRS: Bradley J. Monk
Comprehensive Cancer Center, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, Phoenix (Arizona), USA
Sandro Pignata
National Cancer Institute Fondazione Pascale, Naples, Italy

15:00-15:20 Optimal Assessment of Response in Ovarian Cancer (Recist 1.1 Criteria, CA125…)
Elizabeth Eisenhauer
NCIC Clinical Trials Group, Kingston (Ontario), Canada

15:20-15:45 Update of Randomized Trials in First Line Recurrent Disease
Eric Pujade-Lauraine
Hôpital Hôtel-Dieu, Paris, France

15:45-16:10 Report of the 4th OCCC
GCIG
Gavin Stuart (on behalf of GCIG)

16:10-16:30 Discussion

16:30-17:00 Coffee Break

17:00-17:20 Discussion

17:20-17:30 Remarks and Conclusions
Andrés Poveda
Fundación Instituto Valenciano de Oncología, Valencia, Spain

11:30-12:00 Coffee Break

12:15-13:00 Lunch